Reports on the collaboration between the U.S. Food and Drug Administration (FDA) and the Securities and Exchange Commission to increase their protection of investors against false and misleading statement about FDA-related issues. Provision of an overview of the intra-agency collaboration; Potential effect of the partnership on pharmaceutical companies' pre-approval promotional statements; Details on the approval of drugs for therapeutics.
Processing Request
No Comments.